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Molecul ar Method
Automated testing platforms facilitate the introduction of red 
cell genotyping of patients and blood donors. Fluidic microarray 
systems, such as Luminex XMAP (Austin, TX), are used in 
many clinical applications, including HLA and HPA typing. 
The Progenika ID CORE XT (Progenika Biopharma-Grifols, 
Bizkaia, Spain) uses this platform to analyze 29 polymorphisms 
determining 37 antigens in 10 blood group systems. Once 
DNA has been extracted, processing time is approximately 4 
hours. The system is highly automated and includes integrated 
analysis software that produces a file and a report with genotype 
and predicted phenotype results. Immunohematology 
2015;31:62–68.
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The Progenika ID CORE XT (Progenika Biopharma-
Grifols, Bizkaia, Spain) is a highly automated testing platform 
based on the Luminex XMAP (Austin, TX) testing platform.1–4 
The Luminex system is a modified flow cytometer that utilizes 
probes attached to microspheres and (red and green) lasers to 
quantify the amount of a given analyte that has attached to 
a specific probe. The microspheres are labeled with different 
ratios of two red fluorochromes, creating 100 distinctive bead 
populations or “spectral addresses.” The Luminex system has 
a wide spectrum of applications requiring high-throughput 
detection of multiple nucleic acid sequences in a single reaction 
(multiplexing), including HLA and HPA typing, which 
are potentially of interest in blood centers and transfusion 
services.1 For this reason, Luminex instruments are already 
in place in many laboratories, facilitating the implementation 
and routine use of the ID CORE XT blood group genotyping 
system. 
ID CORE XT analyzes 29 polymorphisms determining 37 
antigens of the Rh, Kell, Kidd, Duffy, MNS, Diego, Dombrock, 
Colton, Cartwright, and Lutheran blood groups, shown in 
Table 1. The less common RhCE alleles assayed are shown 
in Table 2. This is a second-generation assay, replacing the 
ID Core+. In the ID CORE XT system, targeted regions of 
genomic DNA from 10 different red cell blood group systems 
are amplified in a multiplex polymerase chain reaction 
(PCR) using biotinylated dCTP. The amplification products 
are then hybridized onto oligonucleotide probes attached to 
the microspheres and labeled with fluorescence-conjugated 
streptavidin. When the beads are analyzed with the 
Luminex system, the presence of the specific polymorphism 
is determined by the correlation of the fluorescence signal 
intrinsic to each microsphere in the red region of the spectrum, 
with the presence or absence of a corresponding fluorescent 
signal in the green region of the spectrum. An overview of the 
system is shown in Figure 1. The system is highly automated, 
and includes integrated analysis software that produces a file 
with the genotype results and the corresponding predicted 
phenotype. The software helps track samples and reagents 
through the system.
Materials and Methods 
Microscopic spherical particles with a 5.6-micron 
diameter, called microspheres, serve as a solid phase for 
molecular detection. The microspheres are internally dyed 
with two spectrally distinct fluorochromes, red and infrared, 
Table 1. Red cell antigen typing using ID CORE XT
Blood group Variants and ISBT number
Rh C(RH2), E(RH3),c(RH4), e(RH5), CW(RH8), V(RH10), 
hrS(RH19), VS(RH20), hrB(RH31)
Kell K(KEL1), k(KEL2), Kpa(KEL3), Kpb(KEL4), Jsa(KEL6), 
Jsb(KEL7)
Kidd Jka(JK1), Jkb(JK2), JKB_null(IVS5-1a), JKB_null(871C)
Duffy Fya(FY1), Fyb(FY2), FYB_GATA, FYB[265T]_FYX
MNS M(MNS1), N(MNS2), S(MNS3), s(MNS4), U(MNS5), 
Mia(MNS7)
Diego Dia(DI1), Dib(DI2)
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which emit light in different regions of the optical spectrum. 
The combination of the dyes in different concentrations results 
in 100 different fluorescent color tones of red and infrared, each 
color having a unique spectral address defining a bead class. 
Different allele-specific oligonucleotide probes are coupled to 
the microspheres of each bead class. After DNA extraction, 
Table 2. Less common RhCE alleles assayed, ID CORE XT
Allele (ISBT) Allele (ID CORE XT)
RHCE sequences that differ from consensus,  
with underline indicating interrogated positions
RHCE*ceAR RHCE*ceAR c.48C, c.712G, c.733G, c.787G, c.800A, c.916G
RHCE*CeFV RHCE*CeFV c.667T, c.697G, c.712G
RHCE*CeVG RHCE*CeVG c.712G, c.733G, c.787G
RHCE*cEFM RHCE*cEFM c.697G, c.712G
RHCE*ce712G RHCE*ce[712G] c.712G
RHCE*ce733G RHCE*ce[733G] c.733G
RHCE*ce733G,1006T RHCE*ce[733G,1006T] c.733G, c.1006T
RHCE*CE-D(  -  )-CE (various alleles) RHCE*D(2,5,7)-CE c.307, c.676, c.712, c.733, c.10061
RHCE*cE697G,712G,733G RHCE*cE[697G,712G,733G] c.697G, c.712G, c.733G
RHD*DIIIa-CE(3-7)-D 
RHCE*ce48C,733G,1006T
RHD*r′S - RHCE*ce[733G,1006T] IVS3+3100g, c.733G, c.1006T
1Absence of signal for these probe sets.
Fig. 1. Progenika ID CORE XT method. SAPE = streptavidin-phycoerythrin.
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amplification is performed with biotin-labeled nucleotides. 
During hybridization, the amplified sequences bind to the 
oligonucleotide probes. Streptavidin-phycoerythrin (SAPE) is 
used as the labeling molecule that will then bind to the biotin. 
Quantification of each bead class population is performed 
using the Luminex modified flow cytometer. The red laser 
sorts the beads into their different classes, while the green 
laser excites SAPE. The software counts each SAPE signal and 
associates it to the unique bead class. 
The ID CORE XT is considerably simplified compared 
with the early ID CORE+ testing system. An overview of the 
workflow is shown in Figure 2.
The main steps in the procedure (Fig. 2) include:
1. DNA extraction. DNA extraction is performed from 
EDTA whole blood. A total of 100 ng DNA (5 µL) is 
required per sample. DNA concentrations between 
20 and 80 ng/µL are recommended in the ID CORE 
XT package insert. Nevertheless, DNA concentrations 
between 12 and 150 ng/µL were tested during beta-
testing evaluations and gave satisfactory results. The 
genomic DNA purity (A260/A280 ratio) should be in 
the 1.63 to 2.1 range, according to the manufacturer. 
Although DNA concentration can be measured by 
a spectrophotometer, in practice, we have not found 
this necessary. 
2. Amplification. The amplification process, set 
up in the pre-PCR area, includes preparing a PCR 
mix by adding the HotStarTaq (Qiagen, Venlo, the 
Netherlands) polymerase (2.5 U/reaction) to the ID 
CORE XT PCR “master mix,” containing the primers, 
biotinylated nucleotides, and buffer solution together. 
A total of 20 µL of this mixture is then added to the 
PCR plate for each sample and control, followed by 
100 ng of each DNA sample in a volume of 5 µL. The 
plates are sealed with an adhesive PCR plate film, 
centrifuged briefly to collect the liquid at the bottom 
of the wells, and placed in the thermal cycler in the 
post-PCR area. Amplification requires 2 hours, 40 
minutes.
3. Hybridization and labeling. After vigorous 
mixing, 46 µL of the “beads master mix” is dispensed 
into each well of a Costar plate (Bio-Rad Laboratories, 
Hercules, CA). For each sample, 4 µL of the PCR 
product is added to each well. The plate is covered and 
placed in the thermal cycler at 52°C for 30 minutes. 
SAPE in a dilution buffer is then added to each well. 
After labeling with SAPE, the samples should be 
analyzed immediately in the Luminex.
4. Quantification. Quantification of the relative 
amounts of labeled PCR product hybridizing to each 
Fig. 2. Progenika ID CORE XT workflow.
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microsphere is fully automated and takes 30–45 
minutes.
5. Results analysis. The analysis software auto-
matically imports the quantification data from the 
Luminex and produces a report with the genotype 
and predicted phenotype. Footnotes are used for 
possible alternate genotypes or for phenotypes 
predicted to have weak, partial, or variable antigen 
expression. For example, a genotype interpreted 
as RHCE*Ce, RHCE*cE, may have a footnote “also 
possible although less likely: RHCE*ce, RHCE*CE.” 
A homozygous RHCE*ce (733G) genotype will have 
a predicted c+ phenotype with the footnote “detected 
as partial by some reagents” and e+ phenotype with 
the footnote “detected as weak or partial by some 
reagents.”
The instrumentation needed includes:
1. Thermal cycler: The ID CORE XT system has been 
validated for both the gold-plated and the aluminum-
plated 96-Well Geneamp PCR System 9700 (Thermo 
Fisher Scientific, Waltham, MA), and for the Veriti or 
Veriti Dx 96-Well Thermal Cycler (Thermo Fisher 
Scientific, Waltham, MA).
2. Luminex LX 100 or LX 200 instrument with the 
Luminex 100 IS or xPONENT software, respectively.
3. Non-refrigerated microcentrifuge. 
Strengths and Limitations
Ease of Use
The system can test from 6 to 94 samples, with two 
controls. The flexibility in the number of samples is useful, 
permitting more urgent diagnostic testing on relatively 
small numbers of samples as well as donor testing on larger 
sample batches. As detailed in Materials and Methods, the 
amplification and hybridization steps involve little pipetting, 
since reagents have been combined in “master mixes.” Once 
the samples are entered into the Luminex, the system is 
totally automated. The overall time to analyze the samples, 
once the DNA has been extracted, is approximately 4 hours. 
Because the system is automated and uses software to 
interpret the results, little actual expertise in the molecular 
biology of the red cell antigen systems is required, although 
the possibility of visualizing the raw data graphs may provide 
some insight in cases of discordances between phenotyping 
and genotyping or “No Call” results. The software is common 
to other BLOODchip ID XT (Progenika Biopharma-Grifols) 
genotyping systems, such as the ID HPA XT, which allows 
simultaneous sample processing and data analysis in hybrid 
batches.
In summary, the procedure is rapid and simple, requiring 
less hands-on time and a faster turn-around time than the 
earlier version of the system. The speed and flexibility make 
it optimal for analyzing both patient and donor samples. 
Limitations to the system include the impossibility to reread 
a sample and the separate acquisition of the plates used for 
amplification and hybridization. 
Data Handling
Data from the Luminex can be uploaded into a laboratory 
information system and formatted for XML, ASTM, or HL7 
files. This is a major advantage, particularly in the testing 
of donor samples. Currently, at Canadian Blood Services 
(CBS), we are developing a database containing the results 
of donor testing, to allow donors with given genotypes to be 
easily searchable. Once the technology is licensed in Canada, 
we would like to export these results into our eProgesa 
operating system. Similarly, different blood centers in Europe 
are also adapting the communication protocol between the 
XT software and their laboratory information systems to 
automatically upload results into their blood center donor 
database. The immunohematology reference laboratory of 
the Blood and Tissue Bank in Barcelona is also adapting the 
automatic transfer of patient blood group genotype results to 
the laboratory information system, avoiding the risk of manual 
transcription errors. 
Systems Interrogated
ID CORE XT tests for the presence of 29 polymorphisms 
in 10 blood group systems (Table 1). The system is closed, in 
that laboratory users cannot add polymorphism content. The 
xMAP technology is open, however, and this makes upgrading 
the system possible by the manufacturer in future versions. A 
major improvement over the earlier version of the test is the 
detection of more RhCE variants: the low-incidence antigens 
V (RH:10) and VS (RH:20) and the high-incidence antigens 
hrS (RH:19) and hrB (RH:31) (Table 2). These antigens are of 
great interest in the predominantly black patient population 
with sickle cell disease. Investigation and transfusion support 
of these patients is an important component of the service 
provided by our reference laboratories. Challenges related to 
these complex antigens are outlined in the following section. 
Other advantages are inclusion of the GYPB*Mur, YT*A/YT*B, 
and some JK null alleles into the platform. The LU*A/LU*B 
system alleles have also been added in this version of the 
system. The inclusion of low-incidence polymorphisms is useful 
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for the reference laboratory, because it permits elimination of 
the possibility of rare specificities in alloimmunized patients. 
Discrepant results between serology and genotyping can 
occur because of an allele drop-out in assays using primer 
elongation, but the probe hybridization-based ID CORE assay 
is not affected.
Limitations include the absence of the SC*1/SC*2 and the 
LW*A/LW*B alleles. The system does not include RhD, or the 
ABO system. The system also does not provide information 
on zygosity or haplotype determination. As with any system, 
not all rare polymorphisms are interrogated; therefore, there 
may be discordances between genotyping and phenotyping 
results.
Challenges Related to Complex Rh Antigens
One limitation of targeted genotyping platforms derives 
from the restricted number of relevant polymorphic positions 
that they interrogate because of “space” constraints. This 
limitation becomes more evident for high-incidence antigens, 
such as hrB and hrS, for which expression can be affected by 
genetic variants at multiple positions. In particular, hrB and hrS 
prediction is based on the sequence at polymorphic positions 
c.676, c.712, and c.733, although their expression can also be 
affected by variant sequence at c.254, c.538, and c.667. ID 
CORE XT predicts V and VS antigens based on the sequence at 
three polymorphic positions, namely, c.712, c.733, and c.1006. 
Although c.733 is the key position, the sequences at c.712 and 
c.1006 can modulate its effect, as is the case for RHCE*ceAR 
and RHCE*ce48C,733G,1006T alleles, respectively. The effect 
of the sequence at c.733 on V and VS can also be modulated 
by variant sequence at c.340, found in the RHCE*ce340T, 
733G (RHCE*ceJAL), allele. This polymorphic position is not 
interrogated by ID CORE XT, although the variant frequency 
is significantly lower than that at positions c.733 or c.1006.
The accuracy of phenotype prediction for these complex 
antigens is inversely proportional to the population frequency 
of uninterrogated variants. Although this may appear as a 
critical limitation, only a portion of genotype miscalls translate 
into erroneous phenotype predictions. Genotyping platforms 
have implemented various ways to mitigate or avoid the 
consequences of such limitation. First, interrogated positions 
are selected on the basis of their relevance (i.e., their effect on 
antigen expression) and their population frequency, where 
the latter may refer to the global population or to a specific 
race. Second, the data analysis software is designed to make 
default calls for the more likely genotypes, with likelihood 
being a function of variant and haplotype frequencies. Third, 
nomenclature that is inclusive of all the alleles that might 
explain the variant sequences identified is used. Finally, as 
mentioned in Materials and Methods, footnotes are included 
in the report to inform the user of alternative interpretations of 
the data (other possible genotypes and predicted phenotypes).
Licensure
The system is currently CE-IVD marked since June 2014, 
but as of September 2015 has not yet received licensure by the 
U.S. Food and Drug Administration or by Health Canada. 
Results
Validation and Experience with the Method
The ID CORE XT assay was initially evaluated in a small-
scale pilot study undertaken by Progenika in Spain, in which 
100 genomic DNA samples, previously typed by BLOODchip 
Reference v.4.0, ID CORE+, and sequencing, were tested.5 The 
samples included 57 patients and 43 donors of both white 
and African descent. The genotype results were 100 percent 
concordant with the reference methods. A second validation 
study performed by Progenika on 42 commercial cell line DNA 
samples of diverse ethnic origin demonstrated 100 percent 
concordance with BLOODchip reference v4.0 and sequencing 
data.6 
A performance evaluation study using 86 blood donor 
samples was then carried out at an alpha site (Sanquin Blood 
Supply Foundation, Amsterdam, the Netherlands) with 
the aim to test the ID CORE XT assay and the proprietary 
BIDS XT analysis software with samples previously typed 
serologically.7 Although serology was considered the reference 
method, the samples were also genotyped, when possible, by 
a multiplex ligation-probe amplification (MLPA) molecular 
method developed in-house. The ID CORE XT and the BIDS 
XT software performed correctly in a wide range (60–1000 
ng) of total DNA/assay and in different sample batch sizes. 
The five discrepancies encountered with serologic results were 
resolved by MLPA and sequencing, which showed results 
concordant with ID CORE XT. 
A clinical validation with 1000 samples was then carried 
out at two different sites. The samples were selected following 
the common technical specifications established for blood 
group reagents in Appendix II of European Directive 98/79/
CE. ID CORE XT results for C, c, E, e, K, Kidd, and Duffy 
antigens were compared with results obtained by CE-marked 
serology typing reagents. The remaining antigens (which 
belong to self-certification) were evaluated against serology 
data when commercial antibodies were available or otherwise 
against well-established molecular reference methods (either 
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bidirectional DNA sequencing or BLOODchip Reference). The 
ID CORE XT genotyping results of 100 of the 1000 random 
samples, were additionally compared with results from 
bidirectional DNA sequencing or BLOODchip Reference. The 
high sensitivity and specificity rates obtained for all tested 
antigens highlighted the reliability and accuracy of ID CORE 
XT genotyping. 
The ID CORE XT was validated in Brazil using a total of 
229 donor and patient samples previously genotyped using in-
house genotyping methods or the HEA BeadChip™ (Bioarray, 
Warren, NJ).8 A reproducibility rate of 100 percent, repetition 
rate of 0 percent, and a “No Call” or invalid result rate of 1.7 
percent were observed. Results were concordant with previous 
genotyping in 223 out of 229 (97.4%) samples. Four of the six 
discordant samples involved the low-incidence RhCE variants 
V (RH:10) and VS (RH:20). In three of these samples, genomic 
sequencing results were concordant with the ID CORE XT, 
and, in one sample, results were concordant with the HEA. 
One sample was identified as possible r′S by HEA, but was not 
confirmed by ID CORE XT, Beadchip RhD and RhCE kits, or 
sequencing. ID CORE XT uses the IVS3+3100a>g SNP present 
in all type I r′S variants to accurately predict this phenotype. 
Finally, one sample was discrepant for K, with investigation by 
serology and sequencing showing a false-positive result in the 
ID CORE XT.
In a recent international, multicenter study performed at 
three laboratories in Italy, Spain, and the UK, the performance 
in real-life conditions of the ID CORE XT were compared with 
the current methods of the participating centers. Excellent 
results of concordance and processing time were obtained in 
the more than 250 samples tested, which included a number 
of low-incidence rare variants. Publication of the complete 
results of both the clinical validation and the multicenter study 
is in progress (personal communication, N. Nogues). A small 
validation study of 47 hematology patients was also carried out 
in the UK, with one discrepant M typing under investigation.9 
Current organizations using this method include CBS 
and Héma-Québec in Canada and Carter BloodCare, Gulf 
Coast Regional Blood Center, Lifeshare Blood Centers, and 
ITxM/Virginia Blood in the United States. Over 27,000 
samples have been tested internationally using ID CORE XT, 
including several hundred samples in Barcelona and at CBS. 
In Brazil, in-house validation is currently being performed at 
the Molecular Immunohematology Laboratory, Hemocentro-
State University of Campinas, Sao Paulo. Clinical applications 
include testing of selected donors (e.g., donors who may be 
U– or U+var on serologic testing), and investigation of difficult 
patient samples (e.g., patients with autoantibodies). The 
number of alleles interrogated, particularly in the Rh system, 
assists in genotyping patients with sickle cell disease and black 
donors who might express similar variant alleles.
Conclusion
In conclusion, the Progenika ID CORE XT is a highly 
automated testing platform, permitting testing on small or 
larger sample batches. Implementation is relatively easy, 
particularly because the Luminex platform is already in use 
in many immunohematology laboratories. Testing is rapid 
and simple, with integrated analysis and report generation. 
As with any genotyping platform, not all alleles are probed by 
the system, and results must be interpreted considering the 
clinical context and serologic findings.
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